How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,414 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Betafoam Diabetes Mellitus Foot Study

the efficacy and safety of Medifoam® and Betafoam®, which is a new dressing that contains povidone-iodine, in patients with diabetes foot ulcer. 70 patients (35 each arm) are targeted to be enrolled in this study. Treatment follow periods are 8weeks. Condition or disease Intervention/treatment Phase Diabetes Mellitus Foot Ulcer Device: Medifoam® Device: Betafoam® Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 71 (...) Betafoam Diabetes Mellitus Foot Study Betafoam Diabetes Mellitus Foot Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Betafoam Diabetes Mellitus Foot Study The safety and scientific validity

2016 Clinical Trials

122. Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart twice daily and biphasic insulin aspart twice daily in subjects with type 2 diabetes mellitus before, during and after Ramadan. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: insulin degludec/insulin aspart Drug: biphasic insulin aspart Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 263 (...) Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2016 Clinical Trials

123. Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

: Terminated (manufacturing-related issues) First Posted : August 11, 2016 Last Update Posted : March 29, 2018 Sponsor: Janssen Research & Development, LLC Information provided by (Responsible Party): Janssen Research & Development, LLC Study Details Study Description Go to Brief Summary: The purpose of this study is to assess the safety and tolerability of JNJ-64565111 in adult Men and Women (of non-child bearing potential) with Type 2 Diabetes Mellitus. Condition or disease Intervention/treatment Phase (...) Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM) Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2016 Clinical Trials

124. Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

: July 24, 2018 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: semaglutide Drug: empagliflozin Phase 3 Study Design Go to Layout table (...) Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2016 Clinical Trials

125. Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

: Completed First Posted : August 11, 2016 Last Update Posted : August 1, 2018 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug (...) Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2016 Clinical Trials

126. Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

baseline to week 26 in patients with type 2 diabetes mellitus. Secondary Objective: To compare overall efficacy and safety of LixiLan to insulin glargine over 26 weeks in patients with type 2 diabetes mellitus. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010) Drug: Insulin glargine U100 (HOE901) Drug: Metformin Phase 3 Detailed Description: The maximum study duration per patient will be approximately 41 weeks: an up to 14 (...) Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2016 Clinical Trials

127. Environmental Effects Type 1 Diabetes Mellitus

Environmental Effects Type 1 Diabetes Mellitus Environmental Effects Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Environmental Effects Type 1 Diabetes Mellitus The safety (...) : Type 1 Diabetes mellitus (T1D) is characterized by βcell destruction and a long life requirement of exogenous insulin. The bolus basal insulin regimen is a widely accepted therapy concept to treat hyperglycaemia in patients with T1D. This concept requires a very good knowledge of the individuals prandial and basal insulin requirements. However, insulin requirement depends on insulin absorption from the injection site and the individual's insulin sensitivity which relies on a number of effects

2016 Clinical Trials

128. Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus

control, as measured by change of glycated hemoglobin (HbA1c). The second study objectives are to demonstrate that DW1330 is associated with the mechanism of glycemic control and inflammation pathways. The study is also aimed to investigate the safety of DW1330. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Device: Transcutaneous Electrical Nerve Stimulator (DW1330) Device: Sham DW1330 device Not Applicable Detailed Description: This is a multi-center, prospective, double (...) Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2016 Clinical Trials

129. A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

with metformin plus placebo in subjects with type 2 diabetes mellitus who have inadequate glycemic control on metformin. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Ipragliflozin L-proline Drug: Metformin Drug: Placebo Phase 3 Detailed Description: This is a phase 3, double-blind, randomized study to assess the efficacy and safety of ipragliflozin in combination with metformin compared to metformin plus placebo in subjects in Russia with type 2 diabetes mellitus who have (...) A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2016 Clinical Trials

130. A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose cotransporter 2 inhibitors) in subjects with type 2 diabetes mellitus. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: insulin degludec/liraglutide Drug: insulin glargine Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical (...) A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer

2016 Clinical Trials

131. An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

will be randomized 1:1 to receive either albiglutide (starting dose of 30 milligrams [mg] once weekly for 4 weeks, followed by 50 mg once weekly for 4 weeks) or exenatide (starting dose of 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 4 weeks). The total duration of a subject's participation in the study will be approximately 15 weeks. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: Exenatide Drug: Albiglutide Phase 4 Study Design Go to Layout table for study (...) An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2016 Clinical Trials

132. Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes Full Text available with Trip Pro

to micro- and macrovascular complications in both type 1 and type 2 diabetes mellitus and is associated with mortality in type 2 diabetes. The relation between skin fluorescence and cardiovascular disease also extends to other conditions with increased tissue AGE levels, such as renal failure. Besides cardiovascular complications, skin fluorescence has been associated, more recently, with other prevalent conditions in diabetes, such as brain atrophy and depression. Furthermore, skin fluorescence (...) Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes Glycation is important in the development of complications of diabetes mellitus and may have a central role in the well-described glycaemic memory effect in developing these complications. Skin fluorescence has emerged over the last decade as a non-invasive method for assessing accumulation of advanced glycation endproducts. Skin fluorescence is independently related

2016 Glycoconjugate journal

133. ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers

. Targeted enrollment for this study is up to 6 subjects with a confirmed diagnosis of diabetes and who have foot ulcers. Subjects will each receive a single application of ExpressGraft-C9T1 skin tissue on a single identified study DFU following a 10-14 day run-in period. Any subjects requiring additional treatment will receive protocol-defined dressings through Study Treatment Week 12 as necessary. Enrollment will occur with a minimum of one week between each subject. Condition or disease Intervention (...) Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies Foot Diseases

2016 Clinical Trials

134. Prospective, Comparitive, Randomized Study of Allograft Versus Skin Substitute in Non-healing Diabetic Foot Ulcers

engineered skin substitute, when used to treat diabetic foot ulcers (DFUs). Condition or disease Intervention/treatment Phase Diabetic Foot Ulcer Procedure: Tissue Engineered Skin Substitute Device: Offloading Procedure: Amnionic Membrane Graft Not Applicable Detailed Description: Diabetes affects at least 9% of the population, or approximately 29 million people in the United States. Lower extremity ulcers are a serious complication for people with diabetes. Diabetic foot-related problems are the most (...) Prospective, Comparitive, Randomized Study of Allograft Versus Skin Substitute in Non-healing Diabetic Foot Ulcers Prospective, Comparitive, Randomized Study of Allograft Versus Skin Substitute in Non-healing Diabetic Foot Ulcers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2016 Clinical Trials

135. Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls

bone biopsies. Condition or disease Type 1 Diabetes, Bone Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 78 participants Observational Model: Case Control Time Perspective: Cross-Sectional Official Title: Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls Study Start Date : May 2012 Actual Primary Completion Date : August 2013 Actual Study Completion Date : August 2013 Resource links provided by the National (...) Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2012 Clinical Trials

136. Effect of a Basic Skin Care Product on the Structural Strength of the Skin

, Body Mass Index between 20 and 28 kg/m2, Non-smoker of at least one year, Absence of skin diseases or scars in the skin area of interest, Absence of tattoos in the skin area of interest, Able to give written informed consent, Willing and able to fulfill the study requirements Exclusion Criteria: Known or suspected defect of healing, Diabetes mellitus Any acute or chronic pathology that may interfere with the trial conduct, from investigator point of view, Acute or chronic wounds in the skin area (...) . Jan Kottner, Charite University, Berlin, Germany Study Details Study Description Go to Brief Summary: The main aim of this study is to investigate in a suction blister model, whether the use of a basic skin care formulation increases the mechanical integrity/adhesion of the dermo-epidermal junction. Condition or disease Intervention/treatment Phase Healthy Skin Other: Treatment with petrolatum Not Applicable Detailed Description: The process of aging involves numerous structural and functional

2018 Clinical Trials

137. A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

provided by (Responsible Party): CeQur Corporation Study Details Study Description Go to Brief Summary: The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM). Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Device: PaQ® Insulin Delivery Device Drug: Insulin, Asp(B28)- Not Applicable Detailed Description: This is a prospective (...) A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2015 Clinical Trials

138. A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

therapy in combination with metformin in subjects with type 2 diabetes mellitus. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: insulin degludec/liraglutide Drug: insulin glargine Drug: insulin aspart Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 506 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment (...) A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2015 Clinical Trials

139. TAK-648 in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus

as multiple oral doses of TAK-648 solution at escalating dose levels in healthy participants of Japanese decent and participants with T2DM. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: TAK-648 Drug: Placebo Phase 1 Detailed Description: The drug being evaluated in this study is TAK-648 for the treatment of T2DM. This study will consist of 2 parts: (1) multiple ascending doses in participants with T2DM treated with a stable dose of metformin, (2) multiple ascending doses (...) TAK-648 in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2015 Clinical Trials

140. Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus

Technosphere insulin and of 3 single doses of SC insulin lispro in a euglycemic clamp setting. To assess the pharmacokinetic (PK) characteristics of 3 different single doses of Afrezza inhaled Technosphere insulin and of 3 single doses of SC insulin lispro in a euglycemic clamp setting. To assess the safety and tolerability of 3 different single doses of Afrezza inhaled Technosphere insulin. Condition or disease Intervention/treatment Phase Type 1 Diabetes Mellitus Drug: SAR439065 Drug: Insulin lispro (...) months prior to study (with respect to safety of the patient and scientific integrity of the study). Certified as otherwise healthy for type 1 diabetes mellitus patient by assessment of medical history and physical examination (cardiovascular system, chest and lungs, thyroid, abdomen, nervous system, skin and mucosae, and musculoskeletal system), unless the Investigator considers any abnormality to be clinically irrelevant and not interfering with the conduct of the study (with respect to safety

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>